This study demonstrated that higher level of HMGB1 (≥ 3.83 ng/mL) is significantly associated with higher ORR and longer PFS in patients with NSCLC who underwent anti-PD-1/PD-L1 antibody monotherapy. Here, HMGB1 is linked to non-small cell lung carcinoma.